Dupuytren’s

Dupuytren’s and Transforming Factor Beta Genetics

What is the initial abnormality which ultimately results in Dupuytren’s? Because biologic systems are guided by tiny triggers which start a cascading series of events, tiny differences can have large effects, and the hunt is sometimes for tiny differences early in the game. Transforming Factor Beta One (TGF-ß1) is one of the starting players in […]

Read more ›
Dermofasciectomy reconsidered

There are three mechanical approaches for Dupuytren’s. In order of both increasing problems and long term effectiveness, these are: fasciotomy (cut fascia); fasciectomy (remove fascia); dermofasciectomy (remove both skin and fascia). The popularity of dermofasciectomy and skin grafting has been limited by concerns regarding complications of wound healing and loss of flexion. Some of these […]

Read more ›
Feedback Loops in Dupuytren’s

The best hope for finding a medical cure for Dupuytren’s and other fibrotic conditions is through a better understanding of abnormal cell signalling feedback loops regulating fibrosis. Cellular collagen metabolism regulation is not fully understood. Here are a few puzzle pieces. The protein transforming growth factor beta (TGF-ß), among other things, signals myofibroblasts to produce […]

Read more ›
The Dupuytren Symposium is coming!

As tomorrow’s deadline for abstract submission nears, internet connections are heating up at command central for the 2010 International Symposium on Dupuytren’s Disease. The symposium syllabus looks very exciting, with some amazing new reports. Session topics have solidified as: The Myofibroblast; Genetics and Demographics; Disease Concepts; Collagen and Collagenase; Surgical Treatments; Energy Based Treatments; Manual […]

Read more ›
Needle Release of Dupuytren’s: 2010 Manual of Technique
On: Jan 3, 2010
By: Charles Eaton

Percutaneous fasciotomy for Dupuytren’s contracture is an old procedure, but was reinvented by Dr. Lermusiaux in Paris in the 1980s, who used a small needle rather than a scalpel. This modification allows the procedure to be performed using almost no anesthesia, which gives an unprecedented safety margin: the patient can easily confirm whether nerves or […]

Read more ›
Homeopathy for Dupuytren’s
On: Dec 29, 2009
By: Charles Eaton

HH Reckeweg (1905-1985) in Germany developed the Disease Evolution Table of homeopathic medicine. In this system, Dupuytren’s contracture is classified as a mesenchymal-connective tissue cellular-degeneration phase disease. This should be the starting point for homeopathic physicians to begin developing a homeopathic cure for Dupuytren’s. See where Dupuytren’s fits on the Disease Evolution Table:  http://www.dupuytrenfoundation.org/DupPDFs/1985_Reckeweg.pdf

Read more ›
Machines to Stretch Dupuytren’s Cords
On: Dec 28, 2009
By: Charles Eaton

There is not yet a perfect solution for PIP contractures from Dupuytren’s Disease, or for PIP contractures in general. One approach has been to use temporary skeletal fixation devices to slowly lengthen Dupuytren’s cords and scar tissue. The collagen bundles in Dupuytren’s cords don’t actually stretch: they remodel, disconnecting crosslinks between adjacent strands, sliding adjacent […]

Read more ›
Dupuytren’s, epilepsy, barbiturates and genes: a chemical love …triangle.
On: Dec 26, 2009
By: Charles Eaton

Dupuytren’s has been associated with epilepsy. The type or cause of epilepsy doesn’t seem to matter. What does matter is the specific medication phenobarbitone. Dupuytren’s was not common in epileptics prior to the common use of this medicine, but is very common in people on long term treatment with it: Dupuytren’s will be found in […]

Read more ›